The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Simplified screening criteria were developed and found to identify more high-benefit people for lung cancer screening, especially among some minority groups. Simple alternative criteria identified ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and drug label updates.

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

According to the FDA, Apple’s Sleep Apnea Notification Feature is not intended to diagnose, treat, or aid in the management of sleep apnea.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

Chronic airflow limitation and impaired DLCO were associated with common respiratory symptoms in a middle-aged population.

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.

Use of ultra-short-acting β-blockers (esmolol or landiolol) for persistent tachycardia in patients with sepsis may not reduce mortality.

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.